Skip to Content
Merck

C2250000

Clindamycin hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(7S)-7-Chloro-7-deoxylincomycin hydrochloride, Cleocin

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C18H33ClN2O5S · HCl
CAS Number:
Molecular Weight:
461.44
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
4070786
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

pharmaceutical primary standard

API family

clindamycin

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl.CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)C2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O

InChI

1S/C18H33ClN2O5S.ClH/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);1H/t9-,10+,11-,12+,13-,14+,15+,16+,18+;/m0./s1

InChI key

AUODDLQVRAJAJM-XJQDNNTCSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Clindamycin hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Clindamycin is a semi-synthetic, lincosamide antibiotic that is prepared from lincomycin. It inhibits bacterial protein synthesis by hydrogen bond interactions with the 23S rRNA component of the 50S ribosomal subunit thus inducing dissociation of the peptidyl-t-RNA complex. It has antibacterial activity against Gram-positive cocci and antiprotozoal activity against Taxoplasma.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Antibacterial and antiprotozoal antibiotic of the lincosamide class.
Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under Clindamycin hydrochloride


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Lact. - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Michael C Jewett et al.
Molecular systems biology, 9, 678-678 (2013-06-27)
Purely in vitro ribosome synthesis could provide a critical step towards unraveling the systems biology of ribosome biogenesis, constructing minimal cells from defined components, and engineering ribosomes with new functions. Here, as an initial step towards this goal, we report
John W Barlow et al.
BMC veterinary research, 9, 28-28 (2013-02-13)
Treatment of subclinical mastitis during lactation can have both direct (individual animal level) and indirect (population level) effects. With a few exceptions, prior research has focused on evaluating the direct effects of mastitis treatment, and to date no controlled field
D Gonzalez et al.
Clinical pharmacology and therapeutics, 96(4), 429-437 (2014-06-21)
Clindamycin is commonly prescribed to treat children with skin and skin-structure infections (including those caused by community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA)), yet little is known about its pharmacokinetics (PK) across pediatric age groups. A population PK analysis was performed in